Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Affymax Inc. (AFFY : OTC)
 
 • Company Description   
AFFYMAX INC., is a biopharmaceutical company that is developing a pipeline of synthetic peptide-based drug candidates against clinically validated targets for the treatment of kidney diseases and cancer. Affymax's objective is to discover, develop and commercialize novel therapeutics addressing large unmet medical needs. A collaboration of several venture firms created Affymax as an independent company a spin-out from GlaxoSmithKline. Affymax has leveraged its foundation to become a developer of peptide drugs.Their lead product,Hematide, is a synthetic peptide-based erythropoiesis-stimulating agent in clinical development for the treatment of anemia. Hematide is currently entering Phase THREE clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase TWO clinical trials for the treatment of anemia in cancer patients.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 19,741 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 6.62
52 Week High: $0.09
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.23% 16.27%
12 Week 4.92% 15.35%
Year To Date 6.67% 30.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
19200 STEVENS CREEK BOULEVARD SUITE 240
-
CUPERTINO,CA 95014
USA
ph: 650-812-8700
fax: 650-424-0832
investors@affymax.com http://www.affymax.com
 
 • General Corporate Information   
Officers
Richard M. Brenner - Chief Executive Officer
Mark G. Thompson - Chief Financial Officer
Hollings C. Renton - Director
John A. Orwin - Director
Christi van Heek - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00826A109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 6.62
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©